MTOR and colorectal carcinoma: PIK3CA gene mutation affects approximately 15–20% of CRC patients, leading to the persistent activation of the PI3K/AKT/mTOR signaling pathway, and thus promoting proliferation, invasion, metastasis, and drug resistance [56].